Robecosam AG boosted its stake in shares of PerkinElmer, Inc. (NYSE:PKI) by 4.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 496,922 shares of the medical research company’s stock after purchasing an additional 19,755 shares during the period. PerkinElmer makes up approximately 2.4% of Robecosam AG’s portfolio, making the stock its 5th biggest holding. Robecosam AG owned 0.45% of PerkinElmer worth $36,484,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Cutler Group LP boosted its stake in shares of PerkinElmer by 845.7% during the 4th quarter. Cutler Group LP now owns 2,237 shares of the medical research company’s stock worth $163,000 after acquiring an additional 2,537 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of PerkinElmer by 53.8% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,228 shares of the medical research company’s stock worth $170,000 after acquiring an additional 779 shares in the last quarter. Waldron LP purchased a new stake in shares of PerkinElmer during the 3rd quarter worth about $200,000. Seaward Management Limited Partnership purchased a new stake in shares of PerkinElmer during the 3rd quarter worth about $202,000. Finally, Signition LP purchased a new position in PerkinElmer in the 4th quarter valued at about $207,000. 91.94% of the stock is currently owned by institutional investors.
A number of research analysts recently weighed in on the stock. Robert W. Baird reaffirmed a “buy” rating and issued a $88.00 price target on shares of PerkinElmer in a research note on Friday, January 26th. Barclays raised their price target on shares of PerkinElmer from $69.00 to $73.00 and gave the company an “underweight” rating in a research note on Friday, January 26th. ValuEngine lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Cowen reaffirmed a “hold” rating and issued a $84.00 price target on shares of PerkinElmer in a research note on Friday, January 26th. Finally, Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research note on Monday, January 8th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. PerkinElmer currently has an average rating of “Hold” and a consensus target price of $76.85.
PerkinElmer (NYSE:PKI) last released its earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.03. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. The business had revenue of $641.63 million for the quarter, compared to analyst estimates of $619.14 million. During the same period last year, the company posted $0.83 EPS. The business’s revenue was up 13.2% on a year-over-year basis. sell-side analysts predict that PerkinElmer, Inc. will post 3.52 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 10th. Shareholders of record on Friday, April 13th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date is Thursday, April 12th. PerkinElmer’s dividend payout ratio (DPR) is 10.61%.
In other news, insider Andrew Okun sold 2,273 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $77.86, for a total transaction of $176,975.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Frank Anders Wilson sold 103,656 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $73.94, for a total transaction of $7,664,324.64. Following the sale, the insider now owns 93,624 shares of the company’s stock, valued at approximately $6,922,558.56. The disclosure for this sale can be found here. Insiders sold a total of 120,933 shares of company stock worth $8,929,583 over the last three months. Corporate insiders own 2.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/12/robecosam-ag-increases-holdings-in-perkinelmer-inc-pki.html.
PerkinElmer Company Profile
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.